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“Prophylactic” Valve Replacement
for Mild Aortic Valve Disease at
Time of Surgery for Other
Cardiovascular Disease? . . . No*
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MACC
Los Angeles, California
The issue of prophylactic aortic valve replacement (AVR) or
repair at time of open-heart surgery for other cardiovascular
surgery arises in several clinical situations. For example, at
the time of surgery for 1) rheumatic mitral valve disease, 2)
coronary artery disease (CAD) and 3) ascending aortic
disease.
Severe aortic valve disease. Aortic valve replacement is
recommended in selected asymptomatic patients with iso-
lated severe aortic stenosis (AS), aortic regurgitation (AR),
AS/AR (1–3). Thus, there is probably no controversy that if
AS or AR is severe, “prophylactic” AVR should be per-
formed at time of other valvular, cardiac, coronary and
ascending aortic surgery.
See page 2003
Mild aortic valve disease. RHEUMATIC MITRAL VALVE DIS-
EASE. Sir William Broadbent (4) stated 100 years ago that
“The age of the patient at the time when the lesion is
acquired is the most important consideration in progno-
sis. . . .” This was confirmed in the study of Goldschlager et
al. (5) and also in the current era by the seminal study of
Bonow et al. (6).
More recently, Spagnuolo et al. (7) reported on 174
“young” patients with rheumatic heart disease from Irving-
ton House and Bellevue Hospitals, New York, who were
entered into the registry from 1952 through 1966. Patients
in the “low-risk” group (probably those with less than severe
AR) (Table 1) had an outcome that was better than that of
a patient with a prosthetic heart valve (please see following
section).
In this issue of the Journal, Vaturi et al. (8) report on the
natural history of mild AVD in 131 patients aged 61 6 12
years, and followed from 1975 to 1992 for 13 6 7 years
(range 1 to 33 years, median 13 years) after surgery for
rheumatic mitral valve disease. Of 131 patients, 59 (42%)
had AVD (mild in all); 52 of the 59 (88%) had AR, 1 had
AS and 6 (10%) had mixed AS/AR. At the end of follow
up, 96 (73%) of the patients had AVD; 63 of the 96 (66%)
had AR, 6 (6%) had AS and 27 (28%) had AS/AR. Severe
AS or AR was present in only 2 and 1 patients, respectively;
all 3 initially were in the AS/AR group. It is of interest that
of the 6 patients who required surgery on follow up, 4 were
primarily for re-operation of the mitral valve and only 2 for
severe AS. There are limitations to the study of Vaturi et al.
(8). Of 424 patients with rheumatic mitral valve disease, 83
patients died during the first year (64 in-hospital deaths and
19 died during one year follow-up) and 200 patients had
inadequate follow-up, leaving 131 patients in the study who
were a select group. Nevertheless, the study of Vaturi et al.
(8) is useful; it confirms that even in the current era, and
even in older patients with rheumatic mitral valve disease,
AR and not AS is the more common lesion, and mild aortic
valve disease (AVD) rarely progresses to severe AVD over a
long follow-up period. Therefore, patients with mild AVD
at time of surgery for rheumatic mitral valve disease should
not have surgery for the AVD.
CORONARY BYPASS SURGERY. In developed countries, rheu-
matic fever and rheumatic heart disease are uncommon, if
not rare. Thus, the major clinical issue in these countries
relates to the need for “prophylactic” AVR for mild AS at
time of coronary bypass surgery (CBS).
In 1994, Collins and Aranki (9) described 44 patients
with previous CBS who subsequently had AVR (AS was
“mild to moderate” at the time of CBS) and had a high
operative mortality (19.2%) (Table 2). The study of Collins
and Aranki (9) has served the useful purpose of drawing
attention to the clinical problem of management of associ-
ated AVD. Subsequently, Odell et al. (10) and Fighali et al.
(11) have also shown a higher operative mortality of 17%
and 14%, respectively, for subsequent AVR (Table 2). In the
study of Odell et al. (10), 30/145 (21%) patients also had
other cardiac/vascular procedures in addition to repeat CBS
at time of AVR.
However, three subsequent studies of Fiore et al. (12),
Hoff et al. (13), Sundt et al. (14), and their co-workers
(Table 2) have failed to confirm these findings. Fiore et al.
(12) showed the operative mortality in 28 patients for AVR
subsequent to CBS was 18%, compared with 9.1% for initial
CBS and AVR in 175 patients. The difference was not
statistically significant, and the 10-year survival after AVR
was also not significantly different. Hoff et al. (13) reported
on 23 patients undergoing AVR subsequent to CBS; there
was no hospital mortality, and the five-year actuarial survival
after AVR was 71%. Sundt et al. (14) described 52 patients
who had AVR subsequent to CBS; the hospital mortality
was 7.7% compared with 6.3% (p 5 NS) in 427 patients
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undergoing simultaneous CBS and AVR. There is incom-
plete information about various parameters in most of the
studies (9–14) (Table 2).
The important issues to be considered in these studies
include the following:
1. The studies described patients who had AVR after CBS.
At the time of initial CBS, patients were said to have had
mild/moderate AS or “no AS” (9–14). However, none of
these studies provided any data on patients who had mild
AS or “no AS” at time of initial CBS but who subse-
quently have not needed AVR (15).
Pomerance documented from pathologic studies that calci-
fication, thickening and other abnormalities of valves were
common in older people (16). A subsequent echocardio-
graphic/Doppler study in the population showed that in
people aged 55 to 71 years and 75 to 86 years, “slight”
calcification of the aortic valve was present on echocardio-
graphy in 21% and 43%, respectively, and “severe” calcifi-
cation was present in 7% and 14%, respectively (17). Thus,
it seems plausible that the number of patients in the studies
who required subsequent AVR (9–14) is a very small
fraction of those who can be expected to have had aortic
valve calcification, and thus, AVD at time of initial CBS.
2. The number of patients who needed AVR after CBS was
quite small. For example, in the Collins study (9), 22
patients who initially had CBS at their own institution
needed AVR over a period of 17 years, which averages
1.3 patients per year. Overall, it seems that at each of
these institutions, about two to four patients each year
had AVR following CBS, which is a very small number
compared with the total umber of patients undergoing
isolated CBS or even combined CBS and AVR.
3. There is a price to be paid for performing AVR for mild
AS at time of CBS. This includes a higher operative
mortality for combined CBS and AVR (approximately a
doubling of operative mortality as compared to isolated
CBS) (9), and late mortality (up to approximately 2% to
4%/year) (18,19) and morbidity including reoperation for
prosthetic valve malfunction (up to approximately 2% to
6%/year) (18,19). The average time from initial CBS to
subsequent AVR in the cited studies was about eight
years (Table 2) (9–14).
Table 1. Outcome of Rheumatic AR in “Young” Patients
Cumulative high-risk group†
Mortality at 6 years 30%
Angina at 7 years 60%
Heart failure at 6 years 60%
Mortality or angina or heart failure at 6 years 87%
Cumulative low-risk group
Mortality at 6 years 0%
at 15 years 5%*
Angina at 5 years 2%
Heart failure at 6 years 2%
at 15 years 5%
Mortality or angina or heart failure at 15 years 8%
*The only patient (of the 72 patients) in this subgroup who died had developed two
of the three risk factors described above. †Patients were considered to be in a
cumulative high-risk group if they had systolic blood pressure .140 mm Hg or
diastolic blood pressure ,40 mm Hg, moderate or marked left ventricular enlarge-
ment on chest x-ray and two of three ECG abnormalities (S in V2 1 R in V5
$51 mm, ST segment depression or T wave inversion in left ventricular leads).
Adapted from Spagnuolo et al. (7).
Table 2. Data on Patients Who Had AVR Subsequent to CBS
Collins et al.
(9) 1994
Odell et al.
(10) 1996
Fighali et al.
(11) 1995
Fiore et al.
(12) 1996
Hoff et al.
(13) 1996
Sundt III
(14) 1997
Total no. of patients 44 145 104 28 23 52
Years of study 1975–92 1975–94 1983–93 1980–94 1986–95 1985–96
Time: CBS to AVR (yrs) 8–164 mo. (68) — 9.0 6 3 8 6 4 2–17 (7.6) 7.8 6 4.0
At time of AVR
Age, yrs 52–83 (73) 71 6 7.6 67 6 9 70.4 6 9.1 56–85 (69) 72.9 6 6.2
Angina 38% — 66% Avg. Class 1.7 — 100%
Heart failure 24% 9% 70% — — —
Heart failure 1 angina 36% — — — — —
NYHA: FC III–IV — 76% 59% Avg. Class 2.7 — 53%
LV dysfunction — — 53% Score 8.3 6 3.8 — 78%
Repeat CBS 50% 46% 57% 75% 50% —
Op. mortality 18.2% 17% 14% 18% None (0%) 7.7%
Post op.
Myocardial infarction — — 14% 1.1% 4% 1.9%
Heart failure — — YES — None —
Low cardiac output — — YES 8.7% 9% 15%
Significant complications 45% ?56% 61% — 22% —
Causes of death
Low cardiac CO — 75% Combined 12% — 100%
Sudden death — 25% 80% — — —
— 5 Data not stated; avg. 5 average; CO 5 cardiac output; op. 5 operation.
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4. At subsequent AVR, 46% to 75% of the patients needed
repeat CBS. Thus, if the patients initially had CBS and
AVR, about 50% (Table 2) would presumably have
needed reoperation anyway for graft atherosclerosis,
progression of native CAD or both.
5. Many of the centers in the cited studies are referral
centers. In two studies, 50% (9) and 43% (10) of the
patients had their initial CBS elsewhere. Thus, the initial
evaluation of AS and subsequent follow up presumably
also occurred elsewhere. A large number of patients at
time of subsequent AVR had heart failure, were in
NYHA Functional classes III and IV and had reduced
LV ejection fraction (9–14). Would a more careful
follow up and earlier appropriate therapy have reduced
these and other adverse factors and thus lowered the
subsequent hospital mortality for the AVR? Will the
operative mortality of AVR subsequent to CBS be lower
in the late 1990s?
6. The assessment of severity of AS was not uniform
(9–14). Is it possible that the assessment of the severity
of AS at time of initial CBS and also at time of
subsequent AVR may have been incorrect? For example,
in one study, the aortic valve area (AVA) at time of
initial CBS averaged 1.05 cm2 (12), and some patients
needed subsequent AVR within two months. In another
study, the AVA at initial CBS was as low as 0.9 cm2, and
patients needed subsequent AVR within eight months
(9). Thus, it is probable that in some patients severity of
AS was not correctly diagnosed and AVR should have
been performed at time of initial CBS.
At the time of subsequent AVR, in one study the only
symptom was angina in 38%, the AVA was up to 1.7 cm2
and 50% of the patients needed repeat CBS (9), and the
AS was graded as mild to moderate. In another study, all
patients had angina, aortic valve gradient (were the
gradients mean or peak?) was 36 6 27 mm Hg (some
must have had very small gradients), and vein grafts
demonstrated angiographic disease and vein grafts 7 to
10 years old were routinely replaced (14). Thus, it is
probable that at time of subsequent AVR, some patients
had mild AS, and angina was due to progression of
CAD/graft atherosclerosis.
7. A careful review is needed to learn what is meant by “no
AS,” the limitations of gradients obtained by Doppler
ultrasound and the assessment of severity of AS by
gradients, what criteria should be used to grade severity
of AS and the progression of severity of AS.
In some studies, patients were graded as having “no AS” or
no abnormality of the aortic valve at time of initial CBS, but
the criteria used to make these diagnoses were not provided
(14). Patients who have an ejection systolic murmur across
the LV outflow tract may have a normal valve, a thickened
valve or calcified valve or a stenotic valve. One needs to
distinguish these three conditions. An aortic valve may be
diseased but the orifice of the aortic valve has to be narrowed
by up to approximately 50% before a measurable pressure
gradient is present (20) when pressure gradients are directly
measured. Thus, the presence of no gradient or a small
gradient does not mean the valve is not stenotic. In one
prospective study, the diagnosis of aortic “sclerosis” (a
subjective evaluation) and of AS by echocardiography/
Doppler could not be confirmed on re-analysis in 27% and
20%, respectively (21). Thus, one has to be very careful
about the diagnosis of no AS in patients with diseased
valves.
In several studies, the severity of AS was assessed by
echocardiography and Doppler ultrasound. It must be re-
membered that “None of the echocardiographic techniques
measures intravascular pressure directly” (21). The formula
used for aortic valve gradient (AVG) is DP 5 4v2, which is
a simplification of the Bernoulli equation (21):
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Several assumptions are made to calculate valve gradient by
Doppler ultrasound. These include eliminating the flow
acceleration and viscous friction factors, and ignoring the
proximal velocity (22), and that energy losses, nonuniform
velocity profiles, unsteady flow and omission of the up-
stream velocity also affect the accuracy of Doppler assess-
ments of pressure drop (23).
Gradients obtained by Doppler estimate gradients at the
level of the valve whereas gradients obtained a few centi-
meters distal to the aortic valve after pressure recovery has
occurred are more meaningful for the circulation (24).
Doppler gradients are liable to be incorrect in patients with
high cardiac output and in those with small annuli and
eccentric orifices (23). The latter two conditions occur fre-
quently in older patients (.60 years), especially if the stenosis
is judged to be moderate (23). In the cited studies at the time
of CBS, the patients were in their sixties (Table 2).
The gradient across an aortic valve is related to flow
across the valve in systole and is a per beat, and not a per
minute, function (25). Thus, AVG is related to forward
stroke volume from the LV and to systolic ejection time
both of which are a function of heart rate, and of LV
preload, afterload and myocardial contractility (3,26,27). In
addition, because of two obstructions in-series (stenotic
aortic valve and systemic arterial resistance), the gradient is
also influenced by systolic pressure proximal to the distal
stenosis, that is, in the ascending aorta. Thus, AVGs, no
matter how they are obtained, may change within minutes
and do decrease over months of follow-up (Fig. 1). Otto et
al. (28) have documented that AVG may not even increase
when the AV stenosis worsens.
In 636 patients studied by cardiac catheterization over a
10-year period, no AVG (peak or mean) was found that was
both sensitive and specific for severe AS. A mean gradient
of $50 mm Hg or a peak gradient of $60 mm Hg were
“specific” with a 90% or more positive predictive value.
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However, it was not possible to find a lower limit with 90%
negative predictive value. The authors emphasized the
importance of measuring AVA in all patients with suspicion
of severe AS with cardiac catheterization gradients mean of
,50 mm Hg (present in 50% of patients in their study) and
peak of ,60 mm Hg (present in 47% of patients in their
study) (29).
Peak gradient by Doppler ultrasound measures velocity of
blood flow in the earliest part of systolic ejection at a time
which may not necessarily be associated with peak blood
flow in AS. In the normal heart, the dynamics of LV
ejection are primarily inertial in character (not resistive) and
the major phenomenon relating pressure and flow in the
ascending aorta is that governing mass acceleration (30). If
mass acceleration, and thus, velocity of blood flow is
increased, a systolic gradient in early systole can be docu-
mented in normal hearts, both in animals (30) and in
humans (31). Furthermore, these early systolic gradients can
be markedly increased with inotropic stimulation in normal
hearts both in experimental animals (32) and in humans
(31). Peak gradients calculated from Doppler recordings
occur in early systole, which may thus not be related to valve
stenosis or may be exaggerated by valve stenosis. Therefore,
it is better to measure mean AVG.
The stenotic valve area is inversely related not to the
mean AVG but to the square root of the mean AVG. The
95% confidence interval of Doppler mean AVG to that
obtained by simultaneous gradient at cardiac catheterization
is 620 mm Hg (26,27,33). Therefore, a suggested grading
of severity of AS by gradient obtained by Doppler ultra-
sound is that (26,27): AS is highly likely to be severe if the
peak gradient is $80 and mean gradient is $70 mm Hg, AS
is probably severe if peak gradient is 60 to 79 and mean
gradient is 50 to 69 mm Hg and the AS severity is uncertain
if peak gradient is ,60 and mean gradient is ,50 mm Hg
(26,27,29).
The severity of AS can be graded on the basis of AVA
obtained at cardiac catheterization and the subsequent
natural history data on follow-up. These are extensively
referenced in the cited review (Table 3) (26,27). The
calculation of AVA by the method of Gorlin and Gorlin
(34) was criticized 45 years ago (35), but it is still widely
used, is clinically useful and has stood the test of time
(26,27).
Progression of severity of AS has been cited as an issue
that should be considered for recommending AVR at time
of initial CBS. Progression has been assessed by changes in
pressure gradients and AVA. The pressure gradient is said
to increase by 10 to 15 mm Hg/year (28,36–43). In some
patients it increases by as much as 15 to 19 mm Hg/year,
while others show little or no change or even an actual
decrease (Fig. 1).
AVAs are said to decrease by 0.1 to 0.3 cm2/year
(42– 46) and the average rate of change has ranged from
0.10 to 0.15 cm2/year. The 95% confidence limit of
Echocardiographic-Doppler derived AVA to that ob-
tained by cardiac catheterization ranges from 60.4 to
0.8 cm2 (26,27). A small AVA by Doppler ultrasound
may result partly from measured small LV outflow tract,
which can lead to an erroneous overestimation of the
severity of AS (17). Moreover, Otto et al. (28) have
documented that although stenosis severity progresses
more rapidly in patients who develop symptoms requiring
AVR, these patients cannot be identified at the initial
study.
There are problems with the evaluations of progression of
severity of AS. Progression of AS is not uniform in all age
groups, it is more rapid in older patients and in those with
calcific (“degenerative”) AS (46). In the studies that had
repeat cardiac catheterization to assess progression of AS,
(38,40,42,44–47) there presumably had to be a clinical
reason to repeat the cardiac catheterization. In most of the
echo-Doppler studies, the data were obtained from a retro-
spective review of patient records rather than as a prospec-
tive study of consecutive unselected patients. The follow-up
study in some patients has been as little as two to three
months, (42) (Fig. 1) 3, (43) 4, (46) 6, (28,40) 7, (38) 11,
(41) 12 (39) and 13 (36) months and the initial change in
AVG/AVA were then extrapolated to calculate percent
change per year (linearized rate). However, progression of
Figure 1. Change in mean aortic gradient (MG) versus interval of
follow up. The r value of the regression equation was 0.40 after
excluding one outliner. In some patients, the follow-up was about
60 to 90 days. Many patients had a reduced gradient at follow up,
and at 1,000 days, the change in gradient ranged from about 250%
to 1200%; at about 750 days the change in gradient was almost
2100%. Reproduced with permission from Brener et al. (42).
Table 3. Suggested Grading of the Degree of Aortic Stenosis
Aortic
Stenosis
AVA†
(cm2)
AVA Index
(cm2/m2)
Mild . 1.5 . 0.9
Moderate . 1.0 to 1.5 . 0.6 to 0.9
Severe* # 1.0 # 0.6
*Patients with an aortic valve area that is at a borderline value between the moderate
and severe grades (0.9 to 1.1 cm2; 0.55 to 0.65 cm2/m2) should be individually
considered for reasons discussed in the text. The AVA index was calculated on basis
of an average BSA of 1.75 m2. †Criteria for AVA derived from natural history studies
after cardiac catheterization. Reproduced with permission from Rahimtoola (55).
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AS does not necessarily occur in a linear manner but usually
in a stepwise manner (Fig. 2). Furthermore, depending on
the time interval used to obtain the linearized rate, the rate
of change can vary over a very wide range, for example, from
0.004 cm2/year to 1.3 cm2/year (Fig. 2). When an event
does not occur in a linear or a reasonably linear manner and
when follow-up is short (#2 years) or very short (a few
months), it is questionable whether events should be ex-
pressed as a linearized rate per year. One study concluded
that “aortic stenosis progresses predictably over time” (42),
which it does on average; the time to follow-up echocardi-
ography/Doppler ranged from about 30 to 90 days to up to
2,000 days (Mean 1,016 6 482 days) (Fig. 1). However,
many patients had a lower gradient at follow-up and at
approximately 1,000 days the percent change in mean aortic
gradient in an individual patient ranged from about 250%
to 1200% (Fig. 1), and the r value for the relationship after
excluding one outliner was only 0.40. If AVA actually
decreases by 0.10 to 0.15 cm2/year, and if patients initially
had a valve area of 1.6 cm2, then within 10 years all such
patients would be expected to have an AVA of
0.60 to 0.01 cm2, which is unlikely. Moreover, the natural
history study of Horstkotte and Loogen (48) showed that in
149 patients with initial AVA of .1.5 cm2 by cardiac
catheterization, 20 years later 63% of patients still had mild
AS. This relatively benign natural history of mild AS
(.1.5 cm2) is better than that of any valve replacement
device/procedure currently available. The calculated rate of
progression can be expected to vary and does vary with the
initial AVA. In the cited studies, many patients already had
severe AS at the initial study (28,37–41,46). For example, in
one study, 69% of the patients had severe AS at the initial
study (37), and in one prospective natural history study (43),
the median AVA at entry into the study and at final
follow-up at time of AVR/death was about 1.0 cm2. That is,
many patients already had severe AS at entry into the study.
In brief, mild AS has a more benign outcome than valve
replacement. Assessment of AVD and its severity is not
without problems that must be recognized and taken into
account. Performance of both noninvasive and invasive
procedures, analyses of the data and overall evaluation of the
patient should be done with care by skilled and experienced
personnel. Clinical implications are as follows:
1. The severity of AS at the time of initial CBS should be
carefully and accurately determined.
2. Patients with mild AS and no AS at time of CBS should
not undergo AVR at time of initial CBS.
3. At time of initial CBS, it would be prudent to obtain an
echocardiogram in all patients aged $55 to 60 years. If
the valve is thickened, calcified, or is otherwise abnormal,
the patients should have careful evaluation by skilled and
experienced personnel of both their clinical status and of
the valve.
4. After CBS, patients with valvular abnormality initially
should be followed closely and carefully by appropriately
experienced and skilled personnel for assessment of
progression of AS and for evaluation of symptoms, heart
failure and LV dysfunction. If any of these occur,
patients must be treated promptly and appropriately.
Patients must be treated aggressively for control of
adverse factors for atherosclerosis which are common in
such patients (21). Control of these risk factors is
beneficial for slowing or delaying progression of athero-
sclerosis in native coronary vessels and grafts. These risk
factors are common in older patients with calcific AS
(17,21,43) and may have an etiologic relationship to the
development of calcific AS in the older patient (21,49–
53), either directly or as an autoimmune reaction to
antigens present in the valve (49). Patients must stop
smoking. Lipid abnormalities, hypertension and diabetes
must be corrected, patients should take aspirin and
appropriate hormone replacement therapy if indicated,
provided there are no contraindications to their use.
Regular exercise and attaining an ideal weight are also
desirable, and on follow-up, one needs to carefully
evaluate whether symptoms or abnormal findings are due
to progression and development of severe AS or of
atherosclerosis in the coronary arteries/grafts.
5. In clinical practice, the average rate of change of gradient
and valve area is of very limited value. Patients must be
individualized; they should be carefully evaluated and
followed, particularly those in the older age group who
Figure 2. A male patient aged 41 years had a heart murmur and
aortic stenosis diagnosed at age 20 years. In 1985, he was
asymptomatic, but from a cardiac point of view, he had the classic
physical findings of mild AS. Since 1994; he has had clinical signs
of moderate aortic stenosis. He has remained asymptomatic from
a cardiac point of view but has symptoms related to his rheumatoid
arthritis. He continues to work full time. Mean aortic valve
gradients have ranged from 23 to 27 mm Hg, with peak gradients
from 44 to 67 mm Hg. There was considerable variation in
gradients throughout the follow-up evaluations. Aortic valve areas
by echocardiography/Doppler ultrasound from 1988 to 1998 are
shown. Reduction of valve area appears to be more a stepwise
function, and linear rate of progression varies markedly from .004
to 1.3 cm2/year, depending on the points chosen to calculate linear
rate of progression.
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have mild calcific AS or have valve disease with no
demonstrable gradient.
ASCENDING AORTIC DISEASE. In patients with dissecting
aneurysm of the ascending aorta, AR usually implies that
the dissection has extended down to the aortic root/annulus.
Thus, these patients need aortic valve surgery at time of
surgery for the aneurysm even if the AR is mild (54).
Moderate aortic valve disease. AORTIC REGURGITATION.
With moderate AR, it may be difficult to maintain the
patient on extracorporeal circulation or to wean them off
bypass without AVR. This factor should be considered
when recommending CBS.
AORTIC STENOSIS. Patients with AVA from .1.0 to 1.5
cm2 are considered to have moderate AS (Table 3). Older
patients with calcific AS have more rapid progression of
severity of AS. Thus, it may be clinically prudent to perform
AVR at time of initial CBS in some older patients (.60
years) with moderate calcific AS, especially if the AVA is
from .1.0 to 1.3 cm2 (from .0.60 to 0.75 cm2/m2).
However, once again, clinical judgment is important be-
cause in small persons, AVA from .1.0 to 1.5 cm2 may
actually be mild AS, and in large people, AVA in this range
may actually be severe AS. In such patients, correcting AVA
for body size is of some help in clinical decision making.
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